Among them, the development and clinical application of a targeted inhibitor, i.e., ibrutinib, developed based on the BCR pathway, has greatly prolonged the progression-free survival of CLL patients [5]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.